Asia-Pacific IBD therapeutics market is estimated to grow significantly at a CAGR of around 5.5% during the forecast period. The major economies which are contributing to the market are China, India, and Japan. The market growth in these countries is mainly attributed to the growing healthcare infrastructure due to substantial government spending in the healthcare sector. Rapid urbanization and changing eating habits are also supposed to grow the market substantially in the region. Japan contributes significantly to the IBD market in the Asia-Pacific due to growing awareness about IBD and the established healthcare industry. Along with these economies, Australia, Indonesia, and Thailand are other major regions with advanced healthcare facilities and will show a significant growth rate during the forecasted period.

Request a Free Sample of our Asia-Pacific Inflammatory Bowel Disease (IBD) Therapeutics Market: https://www.omrglobal.com/request-sample/asia-pacific-ibd-inflammatory-bowel-disease-therapeutics-market

Asia-Pacific IBD therapeutics market is segmented on the basis of disease type and treatment type. The disease type segment includes ulcerative colitis and Crohn’s disease. Crohn’s disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn’s disease than ulcerative colitis. For Crohn’s and ulcerative colitis, the development of minimally invasive methods has been evolved with more caution as compared to other colorectal diseases. This is primarily due to disease-related characteristics that are concerned with IBD. The treatment type segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. These are usually the first step in the treatment of IBD.

A full Report of Asia-Pacific Inflammatory Bowel Disease (IBD) Therapeutics Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-ibd-inflammatory-bowel-disease-therapeutics-market

Asia-Pacific Inflammatory Bowel Disease IBD Therapeutics Market Segmentation

By Disease Type

• Ulcerative Colitis
• Crohn’s Disease

By Treatment Type

• Surgery
• Anti- Inflammatory Drug Administration
• Steroids
• Immunosuppressant
• Biological Drugs
• Amino salicylates
• Others
Regional Analysis

• China
• India
• Japan
• Rest of Asia-Pacific
Company Profiles

• AbbVie Inc.
• Allergan, PLC
• Boehringer Ingelheim International GmbH
• Daiichi Sankyo Co. Ltd.
• Eli Lilly and Co.
• Johnson & Johnson Services Inc.
• Mercator Pharmaceutical Solutions
• Pfizer Inc.
• RPG Life Sciences Ltd.
• Sanofi S.A.
• Takeda Pharmaceutical Co., Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-ibd-inflammatory-bowel-disease-therapeutics-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 7803040404